HLB Life ScienceHLB생명과학
067630 · KOSDAQ · ₩067630 · HLB생명과학
- Market cap
- ₩409B
- Enterprise value
- ₩484B
- P/E
- —
- P/B
- 1.5×
- Dividend yield
- 0.0%
- ROE
- −11.7%
- Net margin
- −60.9%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−37.1% from the high
₩1,608Today: ₩3,330 – ₩3,455₩5,330
Returns
- 1W−11.4%
- 1M+28.1%
- 3M+64.9%
- 6M−22.0%
- YTD−13.4%
- 1Y−22.0%
- Volume today
- 166,644
- 0.1× the 20-day average
- Traded today
- ₩565M
- Listed shares
- 121,917,058
- EPS (12 months)
- −₩272
- Earnings yield −8.1%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 26 of 100 (50 is a normal day for this stock).
- MomentumFlat27.8% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Knock-on effects
Knock-on from news elsewhere
HLB · [BioS] HLB, After FDA Approval of 'Rifitu,' Announces Group Mid-to-Long-Term Strategy
Moves with HLB (corr 0.90); moved with HLB on 17 of its 18 biggest days
News about other companies that has, in the past, moved this stock too. Evidence-based, not a prediction.
HLB Life Science stock overview
HLB Life Science (HLB생명과학, KRX: 067630) is listed on KOSDAQ, in the Biotech & Pharma sector. HLB Life Science operates across four segments: medicare (in vitro diagnostic devices, OEM/ODM contract manufacturing, reagents and consumables, validation consulting, and B2C products), bio development (drug and bioartificial organ R&D, including a hemostatic agent pipeline), medical devices (disposable syringes sold under the Sofjec brand, plus nitinol products through Tinico), and energy (solar EPC and industrial waste incineration heat). Its shares closed at ₩3,355 on Oct 27, 2026, up 0.60% on the day, giving it a market value of ₩409B.
Key facts
- Market cap
- ₩409B
- Sector
- Biotech & Pharma
- Latest price change
- +0.60%
- As of
- Oct 27, 2026
- Main business
- HLB Life Science operates across four segments: medicare (in vitro diagnostic devices, OEM/ODM contract manufacturing, reagents and consumables, validation consulting, and B2C products), bio development (drug and bioartificial organ R&D, including a hemostatic agent pipeline), medical devices (disposable syringes sold under the Sofjec brand, plus nitinol products through Tinico), and energy (solar EPC and industrial waste incineration heat).
Quick answers about HLB Life Science
- What does HLB Life Science do?
- HLB Life Science operates across four segments: medicare (in vitro diagnostic devices, OEM/ODM contract manufacturing, reagents and consumables, validation consulting, and B2C products), bio development (drug and bioartificial organ R&D, including a hemostatic agent pipeline), medical devices (disposable syringes sold under the Sofjec brand, plus nitinol products through Tinico), and energy (solar EPC and industrial waste incineration heat). Key medicare customers include Abbott and SD Biosensor, and the company sells syringes to hospitals in Korea and exports to the United States, Saudi Arabia, Vietnam and Mongolia.
- What is the market cap of HLB Life Science?
- The market capitalisation of HLB Life Science was ₩409B at the close on Oct 27, 2026.
- Who are the largest shareholders of HLB Life Science?
- According to the latest official filings, the largest reported holders are HLB (17.79%, as of Jul 1, 2026); Jo Yong-ho (2.70%, as of Dec 16, 2024); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (1.30%, as of Jul 31, 2026).
- When is the next earnings report from HLB Life Science?
- Korean companies rarely announce results dates in advance. Based on when HLB Life Science filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own HLB Life Science?
- Yes. The National Pension Service held 0.07% of HLB Life Science shares as of Dec 31, 2025.
Company profile
HLB Life Science operates across four segments: medicare (in vitro diagnostic devices, OEM/ODM contract manufacturing, reagents and consumables, validation consulting, and B2C products), bio development (drug and bioartificial organ R&D, including a hemostatic agent pipeline), medical devices (disposable syringes sold under the Sofjec brand, plus nitinol products through Tinico), and energy (solar EPC and industrial waste incineration heat). Key medicare customers include Abbott and SD Biosensor, and the company sells syringes to hospitals in Korea and exports to the United States, Saudi Arabia, Vietnam and Mongolia.
Written by AI from the company's latest annual report.
- Korean name
- HLB생명과학
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 백윤기
- Founded
- Jul 1998
- Listed
- Nov 2008
- Listed shares
- 121,917,058
- Fiscal year ends
- Month 12
- Website
- www.hlb-ls.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Investor relations (IR) eventOct 12, 2026
- Acquisition of Bonds Prior to Maturity After Issuance of Convertible Bonds (Including Overseas Convertible Bonds) (13th Series)Aug 31, 2026
- Acquisition of shares in another companyAug 28, 2026
- Sale of shares in another companyAug 26, 2026
- Adjustment of Exchange Price (16th Series)Aug 20, 2026
Titles in Korean until English translations are added.
Also known as: HLB Life Science / HLB생명과학 / 067630 / KRX:067630
Source: KRX statistical information